Please login to the form below

Not currently logged in
Email:
Password:

GSK to develop cancer drugs with OncoMed

GSK and US biotech OncoMed partner to discover, develop and market antibody therapeutics to target cancer stem cells

UK pharmaceutical company GlaxoSmithKline (GSK) and US-based biotech OncoMed Pharmaceuticals have partnered to discover, develop and market antibody therapeutics to target cancer stem cells.

Per the agreement, OncoMed could earn milestone payments of up to USD 1.4bn, based on the achievement of specified discovery, development, regulatory and commercial milestones. The biotech will also receive double-digit royalties on all collaboration product sales.

GSK has secured the option to invest in a future initial public offering (IPO) by OncoMed, which focuses on discovery and development of cancer stem cell antibody therapeutics. The move could signal a future acquisition, depending on the success of the collaboration.

GSK also has option to license four OncoMed product candidates directed at multiple cancer stem cell targets.

11th December 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Is communication failing us?
Compelling people to care in a world oversaturated with news and information...
Are your field teams ready to excel in the new era?
A qualitative research approach to help you critically assess post-pandemic learnings and ignite the potential of meaningful interactions with HCPs....
5 Healthcare Marketing Blunders | How To Avoid Them.
Here are 5 healthcare marketing blunders and how best to avoid them....